Where is BioCryst headquartered?

BioCryst is located in Durham, NC.

Who invested in BioCryst?

BioCryst has 13 investors including Geekdom Fund And Geekdom Fund.

When was the last funding round for BioCryst?

BioCryst closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

biocryst.com

BioCryst

BioCryst is a North Carolina-based biotechnology company that develops and commercializes novel oral therapeutics for the treatment of various diseases.

Business Model:

Revenue: $238.4M

Employees: 201-500

Geographic Data

Address: 4505 Emperor Boulevard

City: Durham

State: NC

Zip: 27703

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$350M

Raised Total:

$1B

Social

Twitter

Crunchbase

Metrics

3,543,905Website Global Rank

3,905Website Monthly Traffic

Twitter Followers

Description

BioCryst is a North Carolina-based biotechnology company that develops and commercializes novel oral therapeutics for the treatment of various diseases.

Contact Phone:
+19198591302

Contact Email:

IPO Details

BioCryst went public on 3/4/1994 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
3/4/1994

Ticker Symbol:
BCRX

Live

Opened: -/share

EBITDA	-
Total Cash	-
Total Debt	-
Total Revenue	-
Total Profit (Gross)	-
PE Ratio	-

Investments

Announced Date	Company	Transaction	Money Raised

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
11/2021	Post-IPO Equity		$0	Ontario Municipal Employees Retirement System Royalty Pharma Ontario Municipal Employees Retirement System Royalty Pharma
9/2018	Grant		$0	Centers for Disease Control and Prevention Centers for Disease Control and Prevention
12/2020	Post-IPO Debt		$0	Royalty Pharma Athyrium Capital Management LP Athyrium Capital Management LP Royalty Pharma Royalty Pharma Athyrium Capital Management LP Athyrium Capital Management LP Royalty Pharma
9/2016	Post-IPO Debt	1	$23M	MidCap Financial MidCap Financial
9/2013	Grant	1	$5M	National Institute of Allergy and Infectious Diseases National Institute of Allergy and Infectious Diseases
12/2013	Grant		$2.5M
8/2014	Grant		$2.4M
9/2017	Post-IPO Equity		$92M
8/2014	Post-IPO Equity	1	$4.1M	National Institutes of Health National Institutes of Health
6/2020	Post-IPO Equity		$115M
11/2019	Post-IPO Equity		$63M
12/2020	Debt		$200M	Athyrium Capital Management
5/2020	Post-IPO Equity		$115M
2/2019	Post-IPO Debt	1	$100M	MidCap Financial MidCap Financial MidCap Financial MidCap Financial
5/2020	Post-IPO Equity		$82M
8/2020	Grant		$44M
8/2018	Post-IPO Equity		$57.5M
9/2018	Post-IPO Equity		$3.5M
6/2014	Post-IPO Equity		$1.9M
11/2021	Post-IPO Equity	2	$350M	Royalty Pharma Athyrium Capital Management, LP OMERS Royalty Pharma Ontario Municipal Employees Retirement System Ontario Municipal Employees Retirement System Royalty Pharma
12/2020	Post-IPO Debt	2	$325M	Royalty Pharma Athyrium Capital Management LP Athyrium Capital Management LP Royalty Pharma Royalty Pharma Athyrium Capital Management LP Athyrium Capital Management LP Royalty Pharma
9/2018	Grant	1	$34.7M	Centers for Disease Control and Prevention Centers for Disease Control and Prevention

Acquisitions

Announced Date	Name	Price
10/2012	Presidio Pharmaceuticals
10/2010	Bioanalytical Laboratory Services

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details